Takeda wins long-awaited US approval for first oral drug for eosinophilic esophagitis
The FDA on Monday approved Takeda’s Eohilia, the first oral drug for patients with eosinophilic esophagitis (EoE) in the US, which the company briefly abandoned after receiving a complete response letter.
Takeda will now have to compete with Sanofi and Regeneron’s blockbuster Dupixent, which won its expanded approval in EoE in 2022. EoE causes inflammation of the esophagus, leading to vomiting, difficulty swallowing and pain.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.